Astex signs Genentech breast cancer deal worth more than $490 million

The exclusive worldwide research collaboration gives Genentech rights to Astex compounds, with Astex receiving $25 million upfront, milestone payments and tiered royalties on net sales.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.